The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinib.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples